-
1
Asymmetric Total Synthesis and Anti-Inflammatory Activity of Berbamine, Oxyacanthine, and Related Intermediates
Pubblicazione 2025Soggetti: -
2
The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites.
Pubblicazione 2025Soggetti: -
3
Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [14,57,58].
Pubblicazione 2025Soggetti: -
4
-
5
Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites.
Pubblicazione 2025Soggetti: -
6
-
7
-
8
Effects of the weather on the probability of having an abnormally low score (cognitive outcomes) OR:
Pubblicazione 2025Soggetti: -
9
Associations between pre-assessment self-report measures and EMA (14-day) ratings.
Pubblicazione 2025Soggetti: -
10
Effects of the weather on the probability of having an abnormally low score (functional and physical outcomes):
Pubblicazione 2025Soggetti: -
11
-
12
Workflow of untargeted metabolomics in serum samples from children infected with DENV.
Pubblicazione 2025Soggetti: -
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20